Condition
Zoster
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 2 (1)
P 3 (1)
P 4 (2)
Trial Status
Completed2
Unknown1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04047979Phase 2CompletedPrimary
Systems Biology of Zoster Vaccine
NCT05596526Phase 4Recruiting
Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients
NCT06001606Phase 3UnknownPrimary
Immunogenicity, Reactogenicity of Shingrix in SLE
NCT01684072Phase 4Completed
Safety and Immunogenicity Study of Live Attenuated Vaccine Against Varicella Without Gelatin
Showing all 4 trials